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Introduction
Advances in genetics research are extremely important in the treatment and diagnosis of
disease.1 Technological innovations provide researchers with the means to sequence entire
genomes and publicly disseminate the data through private and public genetic databases.2
However, genetic research has raised some ethical and legal concerns.3 Specifically, the increase
in access to genetic information has threatened the genetic privacy of individuals who either
directly or indirectly participate in genetics research.4
Genetic information is considered highly sensitive and private for several reasons.5 Access
to an individual’s genetic information will disclose that person’s traits, disease patterns, and
family history.6 Consequently, if this information is disclosed to the wrong person, that person
could gain access into an individual’s future, past, and present.7 Critics of the availability of
genetic information believe that it will be used unfairly in employment practices.8

A

discouraging genetic makeup could reduce employment prospects or even cause an employer to
deny an employee insurance coverage based on genetic information received.9 The availability
of genetic research may also be used by insurance providers in making coverage decisions.10
In response to the aforementioned privacy concerns of genetic research, federal legislation
has been developed and amended.11 Congress recently enacted the Genetic Information and
1

Kristie Sosnowski, Genetic Research: Are More Limitations Needed in the Field, 15 J.L. & HEALTH 121, 136 (2001).
Sarah Fendrick, The Role of Privacy Law in Genetic Research, 4 J.L. & POL’Y FOR INFO. SOC’Y 803, 804 (2008).
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Nondiscrimination Act of 2008 (hereinafter “GINA”) to restrict the use of genetic information by
insurance and health care providers and in employment practices.12 Also, the Health Insurance
Portability and Accountability Act of 1996 (hereinafter “HIPAA”), was enacted to ensure the fair
use of genetic information by insurance providers13 and to preserve the confidentiality of an
individual’s protected health information.14 However, the incomprehensive nature of the federal
legislation has prompted states to enact laws that address the privacy concerns of genetic
research.15
This article first provides a basic understanding of genetic testing and research of human
tissue samples. Next, this article will provide an overview of the major federal legislation, GINA
and HIPAA, which have been passed in an effort to remedy the privacy concerns of genetics
research. Furthermore, the article will discuss whether the states have adequately supplemented
the federal legislation. This article will primarily focus on New Jersey and New York law as it
will be argued that other states should adopt a similar statutory framework in order to establish
more uniform and stringent laws on the use and disclosure of genetics research. Finally, this
article will propose solutions to effectively address the individual privacy concerns of genetics
research while still allowing for the scientific advancement of genetics research in order to
benefit humanity.
I. Genetic Tests and their Administration
A genetic test has generally been as defined as the analysis performed on human
deoxyribonucleic acid (hereinafter “DNA”), ribonucleic acid (hereinafter “RNA”), genes and/or
12

Id.
Id. at 140.
14
Elizabeth Hutton & Devin Barry, Privacy in Review: Developments in HIPAA, 1 J.L. & POL’Y FOR INFO. SOC’Y 347, 347
(2004).
15
Fendrick, supra note 2, at 804.
13
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chromosomes in order to detect heritable and acquired genotypes, mutations, phenotypes, or
karyotypes that cause or are likely to cause a specific disease or condition.16 A genetic test also
is the analysis of human proteins and certain metabolites, which are predominantly used to detect
heritable or acquired genotypes, mutations, or phenotypes.17
Specifically, there are two general types of health-related genetic tests: diagnostic and
predictive.18 Diagnostic tests are used to identify the presence or absence of a disease.19 In
contrast, predictive genetic tests are used to predict whether an individual will develop a genetic
disorder in the future before any signs or symptoms are manifested.20 Early diagnosis and
treatment of severe genetic diseases lead many to believe that the benefits of genetics testing and
research outweigh the risks,21 such as discrimination by employers and/or health insurance
providers if an individual’s genetic information is distributed without their knowledge.22
For example, if a tissue provider learns through genetics research that she carries the gene for
Huntington’s disease, then breaches of confidentiality may be detrimental to the interests of that
tissue provider.23 If third parties, such as an insurance provider or employers gain access to this
information, they may find ways to refuse, limit, or terminate that individual’s insurance,
employment, or other opportunities.24 Also, genetic material identifies not only the individuals

16

Laren E. Nuffort, The Genetic Information Nondiscrimination Act of 2008: Raising a Shield to Genetic
Discrimination in Employment and Health Insurance, 21 no. 5 HEALTH LAW 1, 5 (2009).
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Sosnowski, supra note 1, at 133.
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Id. at 137.
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who provide it, but close family members as well.25 Thus, not only do consenting tissue
providers have a stake in the confidentiality of their genetic information, but so do their genetic
relatives.26 Consequently, genetic information that is disclosed to an unauthorized source, such
as insurance providers or employers, raise substantial privacy concerns.27
Traditionally, researchers have taken a number of steps to protect the confidentiality of tissue
providers.28 Specifically, tissue samples may be coded, meaning that they are assigned a number
that corresponds to a secret file containing identifying information.29

Thus, identifying

information for a particular tissue sample can only be obtained with access to a decoding
program or database.30
Moreover, researchers and institutions may “anonymize” tissue samples, a process designed
to completely and permanently separate the sample from identifying information.31 However,
with emerging technology, it is unclear whether true anonymization can ever be achieved.32
DNA is as individually identifying as a fingerprint, and thus any individual cell could be traced
back to its source.33
On the other hand, society has a profound interest in promoting genetics research using
human tissue in order to advance scientific development.34 In particular, societal interests may
include facilitating researcher access to research materials, incentivizing investment in high

25
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quality research, and ensuring that research is conducted in a responsible and ethical matter.35
Simple and inexpensive access to the raw materials of research is critical to promoting
investment in science and medicine.36 However, if the interests of research participants are
inadequately protected, then potential tissue providers will simply refuse to participate in
genetics research.37

Therefore, the scientific advancement of genetics research should be

balanced with the protection of individual privacy interests.38
II. Overview of Federal Legislation
A. Health Insurance Portability and Accountability Act of 1996
The HIPAA Privacy Rule is the first federal law to protect health information created or
received by health care providers and health plans.39 Specifically, as applied only to “covered
entities,” HIPAA limits the circumstances under which “protected health information” may be
disclosed.40 If an entity is a “covered entity,” it may not disclose “protected health information”
except as required or permitted by HIPAA.41 The Privacy Rule of HIPAA requires covered
entities to adhere to a “minimum necessary” standard when disclosing protected health
information.42 The “minimum necessary” standard provides that when disclosing protected
health information, a covered entity must make “reasonable efforts to limit protected health

35

Id.
Id.
37
Id. at 176.
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Id. at 138.
39
Joanne L. Hustead & Janlori Goldman, Genetics and Privacy, 28 AM. J.L. & MED. 285, 289 (2002).
40
Jonathan Hsu, Genetic Testing: Balancing Preventive Medicine with Privacy and Nondiscrimination, 6 J.L. & POL’Y
FOR INFO. SOC’Y 557, 577 (2011).
41
45 C.F.R. § 164.502 (2013).
42
Id. at § 164.502(b).
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information to the minimum necessary to accomplish the intended purpose of the use, disclosure,
or request.”43
A “covered entity” is defined as “a health plan,” “a health care clearinghouse,” “a health care
provider who transmits any health information in electronic form in connection with a
transaction covered by this subchapter,”44 or a “business associate” of another covered entity.45
A “health plan” is any plan that pays for health care serves such as Medicare, Medicaid, any state
or federal health plan, private health plans, and employer self-funded health plans.46 Health
maintenance organizations also fall within the contours of a “health plan.”47 Additionally, a
“health care clearinghouse” is any entity that compiles health care information,48 such as
computer data processing centers and billing companies, which aggregate and process
computerized health information.49 Moreover, a “health care provider” is anyone who furnishes,
bills, or is paid for healthcare in the normal course of business, such as doctors, nurses,
therapists, hospitals, medical technicians, nursing homes, rehabilitation centers, psychologists,
pharmacists, and therapists.50

Finally, “business associates” of a covered entity are those

individuals and entities, such as lawyers, accountants, or certain vendors, that are required to
have access to and knowledge of “protected health information,” must also abide by HIPAA’s
requirements.51

43

Id. at § 164.502(b)(1).
Id. at § 160.102; 42 U.S.C. § 1320d-1 (1996).
45
45 C.F.R. at § 160.103.
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Furthermore, “protected health information” (hereinafter “PHI”) is broadly defined under
HIPAA as “individually identifiable health information,”52 which does not explicitly include
genetic information.53

However, the U.S. Department of Health and Human Services

(hereinafter “HHS”) has clarified that “genetic information” is covered as “PHI” under the
Privacy Rule.54 Every covered entity is obligated to protect the confidentiality of individually
identifiable information.55 Permitted disclosures of PHI are those disclosures to the individual or
those disclosures for the purpose of “treatment, payment, or health care operations.”56 A covered
entity may also disclose PHI to the extent as required by law.57 Only covered entities are
required to comply with the HIPAA privacy regulations, whereas non-covered entities, such as
research laboratories, are not required to comply.58 Therefore, genetic information used in
research is afforded the same protection under HIPAA as other health care information only if
the researcher is characterized as a “covered entity.”59
In 2013, HHS released final regulations expanding privacy rights for patients and others
under the Privacy Rule of HIPAA.60 The regulations expand many of the requirements to
business associates of entities that receive protected health information, such as contractors and
subcontractors.61 Ostensibly, some of the largest breaches reported to the HHS have involved

52

Id. (“Protected health information means individually identifiable health information that is: (i) transmitted by
electronic media; maintained in electronic media; or transmitted or maintained in any other form or medium.” Id.)
53
Id.
54
U.S. Department of Health & Human Services, Health Information Privacy, March 14, 2006, available at
http://www.hhs.gov/ocr/privacy/hipaa/faq/protected_health_information/354.html (last visited at April 5, 2013).
55
45 C.F.R. at § 164.502(a).
56
Id.
57
Id. at § 164.512(a)(1).
58
Fendrick, supra note 2, at 808.
59
Id. at 809.
60
U.S. Department of Health & Human Services, News Release, Jan. 17, 2013, available at
http://www.hhs.gov/news/press/2013pres/01/20130117b.html (last visited at April 5, 2013).
61
Id.
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business associates.62 Consequently, penalties are increased for noncompliance based on the
level of negligence with a maximum penalty of $1.5 million per violation.63 Also, individual
rights are expanded in important ways.64 Patients can ask for a copy of their electronic medical
record in an electronic form.65 When individuals pay by cash they can instruct their provider not
to share information about their treatment with their health plan.66 There are also limits on how
information is used and disclosed for marketing and fundraising purposes and prohibits the sale
of an individuals’ health information without their permission.67
Moreover, HIPAA addresses the concerns associated with the use of genetic information by
insurance providers.68 HIPAA provides that “genetic information shall not be treated as a [preexisting] condition in the absence of a diagnosis of the condition related to such information.”69
Also, HIPAA precludes insurance providers offering a group health insurance plan from
requiring an individual to pay a higher premium than those similarly situated, based solely on the
individual’s health information, which includes genetic information.70

In essence, HIPAA

prohibits insurers from using genetic information to deny or limit health insurance coverage.71
On the other hand, there are many ways that insurers can obtain and adversely use genetic
information that are not precluded by HIPAA.72 For example, insurers in the group market may
charge an entire group of any size more than another group because of the genetic information of

62

Id.
Id.
64
Id.
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Id.
66
Id.
67
Id.
68
Sosnowski, supra note 1, at 144; 29 U.S.C. § 1182(a)(1)(F) (2008).
69
29 U.S.C. § 1181(b)(1)(B).
70
Id. at § 1881(b)(3)(A).
71
Sosnowski, supra note 1, at 145.
72
Hustead, supra note 39, at 292.
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one individual in the group.73 Also, insurers may request, require, purchase or otherwise collect
an applicant’s genetic information in the group and individual markets.74 Furthermore, insurers
in the group market may refuse to cover an entire group because of the genetic information of
one individual in the group.75
Additionally, employers may learn about the health status and medical conditions of their
employees and dependents, in various ways.76 One important source of this information is
medical examinations required by employers.77

Research demonstrates that employers use

results from medical examinations when making decisions about hiring, placement, retention,
and dismissal.78 Another important avenue for collection of medical information is through
health claims submitted to employer-sponsored health plans.79

All of the ways in which

employers may obtain health information could result in employers obtaining genetic
information.80 An employer that provides health care services to its employees may be a “health
care provider” that is required to comply with the HIPAA regulations.81 Under HIPAA, only
employees involved in plan administration would have access to PHI.82 Although its protections
are substantial, HIPAA does not prevent genetic discrimination by employers.83

73

Id.
Id.
75
Id.
76
Id. at 293.
77
Id.
78
Id.
79
Id.
80
Id.
81
Id. at 291.
82
45 C.F.R. § 164.504(f)(2)(iii).
83
Hutton, supra note 14, at 368.
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Therefore, a substantial inadequacy of the HIPAA regulations is its failure to reach all people
or entities that have access to PHI,84 such as tissue banks or researchers.85 Also, while HIPAA
addresses certain genetic discrimination practices, it was not created for the sole purpose of
preventing genetic discrimination.86

Because HIPAA sets a federal floor of privacy

protections,87 state laws that are less protective of privacy are preempted.88
B. Genetic Information and Nondiscrimination Act of 2008
GINA amended a variety of federal statutes, including HIPAA, in order to limit health
insurers’ use of genetic information in making decisions about plan enrollment and in adjusting
premiums.89 It also regulates how employers may use and store genetic information.90 Pursuant
to GINA, “genetic information” is defined as the following: “(i) the individual’s genetic tests;
(ii) the genetic tests of family members of such individual; and (iii) the manifestation of a disease
or disorder in family members of such individual,”91 which does not include sex or age.92
A “genetic test” pursuant to GINA is defined as “an analysis of human DNA, RNA,
chromosomes, proteins, or metabolites, that detects genotypes, mutations, or chromosomal
changes.”93 But there are exceptions that provide that a genetic test is not “an analysis of
proteins or metabolites that does not detect genotypes, mutations, or chromosomal changes,”94 or
“an analysis of proteins or metabolites that is directly related to a manifested disease, disorder, or
84

Id.
Christina Strong et. al., Healthcare Privacy laws- Covered Entities, 2012 § 10:6 (2012).
86
Hutton, supra note 14, at 376.
87
Hustead, supra note 39, at 292.
88
Id. at 293.
89
29 U.S.C. § 1182(b)(1).
90
42 U.S.C. § 2000ff-1(a) (2008).
91
Id. at § 2000ff(4).
92
Id. at § 2000ff(4)(C).
93
Id. at § 2000ff(7).
94
Id. at § 2000ff(7)(B); Id. at § 300gg-91(17(B)(i).
85
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pathological condition.”95 These definitions under GINA do not provide much guidance as to
the types of tests considered genetic.96
Specifically, Title I of GINA amended HIPAA in order to prevent group health plans and
group health insurance issuers from setting group premium or contribution amounts on the basis
of genetic information.97 Additionally, GINA prohibits plans and issuers from requesting or
requiring an individual to undergo genetic tests, and prohibits a plan from collecting genetic
information (including family history) prior to or in connection with enrollment,98 or for
underwriting purposes.99 Under GINA, underwriting purposes include rules for determination of
eligibility for benefits and the computation of premium and contribution amounts.100 In other
words, plans or issuers are generally prohibited from offering rewards in return for completing a
health risk assessment that requests genetic information, including family medical history.101 An
exception will allow genetic testing to be requested, but not required, for research purposes when
certain conditions are satisfied.102
On the other hand, there are some examples where a health insurance plan may obtain or use
genetic information that are permitted under GINA.103

First, a health insurance plan may

recommend to an individual that he or she may want to undergo a genetic test for purposes of
disease management or prevention.104 However, the health insurance plan may only recommend

95

Id. at § 300gg-91(17(B)(ii).
Mark A. Rothstein, GINA, the ADA, and Genetic Discrimination in Employment, 36 J.L. MED &
(2008).
97
26 U.S.C. § 9802(b)(3) (2008).
98
Id. at § 9802(d)(2).
99
Id. at § 9802(d)(1).
100
Id. at § 9832(d)(10).
101
Eric N. Miller, The Genetic Information Nondiscrimination Act of 2008, 2015, 2016 (2013).
102
26 U.S.C. § 9802(c)(4).
103
Nuffort, supra note 16, at 15.
104
Id.
96
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837, 838

the genetic test to the individual; it cannot request or require that the test be taken.105 Also, when
certain conditions are satisfied, health insurance plans may request that an individual undergo a
genetic test for research purposes.106
Moreover, Title II of GINA amended HIPAA in order to prohibit private employers, state
and federal governmental entities, labor organizations, employment agencies, and joint labormanagement committees from discriminating against an employee based on genetic
information.107 An employer engages in an unlawful employment practice if the employer
requests, requires, or purchases the genetic information of an employee or family member of that
employee.108
However, there are certain exceptions to this prohibition.109

First, an employer who

inadvertently requests or requires an employee’s medical history or an employee’s family
members’ medical history has not committed a violation.110 Second, an employer can offer
health or genetic services whereby an employee gives prior, knowing, voluntary, and written
authorization, and only the employee or employee’s family member and a licensed health care
professional receive the results.111 This information may be available only for purposes of such
services and cannot be disclosed to the employer except in aggregate terms that do not disclose
the employee’s identity.112 Third, an employer may request or require family medical history

105

Id.
Id.
107
42 U.S.C. § 2000ff-1(2).
108
Id. at § 2000ff-1(b).
109
Id.
110
Id. at § 2000ff-1(b)(1).
111
Id. at § 2000ff-1(b)(2)(B).
112
Id. at § 2000ff-1(b)(2)(C).
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from the employee in order to comply with state family or medical leave laws.113 Finally, an
employer is permitted to purchase publicly available documents of family medical history.114
Accordingly, GINA provides that unlawful employment practices include failing to hire,
discharging, or otherwise affecting a term, condition, or privilege of employment resulting from
genetic information received.115 It also prevents an employer from limiting, segregating, or
classifying employees, or tending to deprive them of employment opportunities on the basis of
genetic information.116 Also, in the event that an employer does obtain access to an individual’s
genetic information, such information must be kept on separate forms and in separate medical
files.117 The information must be treated as confidential medical records of the employee.118
A major concern for both employers and insurers is GINA’s overly broad definition of
“genetic test.” 119 The health care industry has recommended that the definition of “genetic test”
be limited to predictive testing performed on asymptomatic or undiagnosed individuals for the
purpose of assessing the risk of future diseases; because the industry was concerned that the
broad definition of “genetic test” would force employers to offer health plan coverage for all
treatments for genetically related conditions.120 Also, the broad definition of “genetic test” may
increase the number of GINA-based lawsuits.121 However, Congress did not adopt the health
industry’s recommendation.122

113

Id. at § 2000ff-1(b)(3).
Id. at § 2000ff-1(b)(4).
115
42 U.S.C. § 2000ff-1(a)(1).
116
Id. at § 2000ff-1(a)(2).
117
Id. at § 2000ff-5(a).
118
Id.
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24, 27 (2011).
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Id. at 27.
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For example, in a recent case, the U.S. District Court for the Western District of North
Carolina held that the plaintiff failed to state a cognizable claim pursuant to Title II of GINA.123
The plaintiff alleged that he was rejected from employment because of his failure to pass initial
screening tests.124 However, the court held that there were no allegations that the employer
asked for or obtained the plaintiff’s genetic information.125 Also, the court held that even if the
employer did obtain the plaintiff’s genetic information, the facts did not suggest that such
information was used to discriminate against the plaintiff.126
Furthermore, the U.S. District Court for the Southern District of Florida dismissed plaintiff’s
complaint without prejudice because it failed to allege that the defendant required him to take a
genetic test, that the defendant had otherwise obtained the plaintiff’s genetic information, or that
the defendant had discovered specific genetic information that caused it to deny employment to
the plaintiff.127 There was also an issue as to the timing of the alleged discrimination.128 Any
alleged violations taking place prior to Nov. 21, 2009, predate the effective date of Title II of
GINA, and thus are not actionable.129
One of the purposes of GINA was to reconcile the various state laws that had been adopted
on the issue of genetic discrimination and establish a “national and uniform basic standard.”130
However, if that was truly Congress’ intent, one would expect Congress to preempt the
legislation in this area.131 Instead, Title II of GINA expressly provides that its provisions cannot

123

Bullock v. Spherion, No. 3:10-cv-465, 2011 WL 1869933, at *4 (W.D.N.C., May 16, 2011).
Id. at *1.
125
Id. at *6.
126
Id.
127
Citron v. Niche Media/Ocean Drive Magazine, No. 10-24014- CIV, 2011 WL 381939, at *2 (S.D. Fla. Feb. 2, 2011).
128
Id.
129
Id.
130
Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 881, § 2(5) (2008).
131
Trimboli, supra note 119, at 28.
124
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be construed to “limit the rights or protections of individuals under any other Federal or State
statute that provides equal or greater protection.”132 This provision seems inconsistent with the
stated intention of creating a uniform national standard.133 Because of varying state laws and the
rapid development of genetic science, there may be unintended consequences that arise from
Congress’ inability to accurately predict future results subsequent to GINA’s adoption134
C. Synthesis
A substantial inadequacy of HIPAA is its inability to reach all entities or persons that have
access to an individual’s PHI. HIPAA applies only to “covered entities” that have access to an
individual’s PHI, which include “genetic information.” Thus, entities such as certain research
laboratories and tissue banks do not have to comply with HIPAA’s regulations and may freely
disclose an individual’s identifiable genetic information to an unauthorized source, such as
employers and/or health care providers. Also, while HIPAA creates some restrictions on the use
of an individual’s PHI, it was not created for the sole purpose of preventing discrimination by
employers and/or health care providers.
On the other hand, GINA amended HIPAA in order to preclude discriminatory conduct by
employers and/or health insurance providers if they gain access to individual’s PHI. However,
while GINA improved the anti-discriminatory provisions of HIPAA, it does not prevent certain
entities, such as research laboratories or tissue banks, from disclosing an individual’s identifiable
genetic information to third parties without authorization.

132

42 U.S.C. § 2000ff-8(1).
Trimboli, supra note 119, at 28.
134
Id. at 27.
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Therefore, federal legislation allows certain researchers and tissue banks to freely disclose to
a third party an individual’s PHI, including identifiable genetic information, without
authorization. Consequently, employers and/or health care providers are still able to gain access
to an individual’s PHI through researchers or tissue banks and possibly make discriminatory
judgments based on this information.

Because of the incomprehensive nature of federal

legislation, the states have implemented laws to effectively address these privacy concerns of
genetics research.
III. Overview of State Legislation
A. “Genetic Information” and “Genetic Test”
Inadequate federal legislation with regard to an individual’s genetic information has
prompted states to pass laws that impose higher standards.135

State protections of genetic

information do not mirror one another, and thus vary widely in their capabilities.136 Many states
have passed legislation that place restrictions on what constitutes a genetic test and place limits
on the collection and disclosure of genetic information.137 These restrictions have varying
effects on genetic research, which depend on the definitions of “genetic information” and
“genetic tests” and how broadly these terms are defined in the legislation.138 Consequently, the
variety of definitions generates difficulty in determining the information that should be
protected.139

135

Fendrick, supra note 2, at 812.
Nuffort, supra note 16, at 9.
137
Fendrick, supra note 2, at 812.
138
Id.
139
Michael S. Yesley, Protecting Genetic Difference, 13 BERKELEY TECH. L.J. 653, 661 (1998).
136
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Accordingly, state legislation that narrowly defines “genetic information” may be easier to
implement, but may not provide sufficient protection.140 For example, Massachusetts provides
that genetic information “shall not include any information about an identifiable person that is
taken: (1) as a biopsy, autopsy, or clinical specimen solely for the purpose of conducting an
immediate clinical or diagnostic test that is not a test of DNA, RNA, mitochondrial DNA,
chromosomes or proteins.”141 Therefore, Massachusetts distinguishes between research and
clinical data.142
In contrast, some states use broad definitions of “genetic test” that do not exclude certain
research from their scope, which may restrict the ability of researchers to use tissue samples.143
For example, “genetic test” is defined in Louisiana as “any test for determining the presence or
absence of genetic characteristics in an individual, including tests of nucleic acids, such as DNA,
RNA, and mitochondrial DNA, chromosomes, or proteins in order to diagnose or identify a
genetic characteristic or that detects genotypes, mutation, or chromosomal changes.”144
On the other hand, many statutes contain language similar to that found in Nebraska, which
excludes from the definition of “genetic test” any activities undertaken as part of biomedical
research: “Genetic test does not include a routine physical examination or a routine analysis,
including a chemical analysis, of body fluids unless conducted specifically to determine the
presence, absence, or mutation of a gene or chromosome.”145

140

Id. at 660.
Mass. Gen. Laws Ann. Ch. 111 § 70G(a)(1) (2000).
142
Id.
143
See, e.g. LA. Rev. Stat. Ann. § 22:213.7(A)(9)(a) (2003).
144
Id.
145
Neb. Rev. Stat. § 77-5519 (2012).
141
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B. Informed Consent
Some states require informed consent from the individual providing the genetic material
before the information and/or material can be disclosed for research purposes.146 Within a
number of states requiring informed consent, specific provisions are included that regulate the
retention and future use of blood and tissue samples.147 Specifically, Delaware, Nevada, New
York, New Jersey, and Oregon have laws requiring researchers to obtain individual informed
consent in order to retain “genetic information.”148
For example, in New Jersey genetic privacy is regulated pursuant to New Jersey’s Genetic
Privacy Act.149

The act prevents employers and insurance companies from discriminating

against individuals on the basis of their genetic information.150 “Genetic information” is defined
as the “information about genes, gene products or inherited characteristics that may derive from
an individual or family member.”151 The act protects genetic privacy by mandating that genetic
information be destroyed after completion of the research project unless individual consent is
obtained to retain the sample.152
Similarly, New York protects the confidentiality of records of genetic tests.153 New York
law imposes stringent requirements for informed consent and retention of samples for limited
periods, but the law permits the research on anonymous samples, pursuant to a research protocol
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approved by an institutional review board (hereinafter “IRB”), when the identity of the
individuals is protected.154 In general, New York prohibits the conduct of “genetic tests” without
the prior written informed consent of the individual.155 A “genetic test” is defined as:
…Any laboratory test of human DNA, chromosomes, genes, or gene products
to diagnose the presence of a genetic variation linked to a predisposition to a
genetic disease or disability in the individual or the individual’s offspring; such
term shall also include DNA profile analysis. ‘Genetic test’ shall not be deemed
to include any test of blood or other medically prescribed test in routine use that
has been or may be hereafter found to be associated with a genetic variation
unless conducted purposely to identify such genetic variation.156
According to the New York statute, valid informed consent must be obtained prior to a
“genetic test.”157 Specific elements must be incorporated into the informed consent form, which
include the following: a general description of each specific disease or condition that will be
tested, the level of certainty that a positive test result for that disease or condition serves as a
predictor of such disease, the name of the person or categories of persons or organizations to
whom the test results may be disclosed, and a statement that no tests other than those authorized
shall be performed on the biological sample.158
For clinical genetic tests, the informed consent must provide that the sample shall be
destroyed at the end of the testing process, or not more than sixty days after the sample was
taken, unless a longer period of retention is expressly authorized in the consent.159 New York
law requires individual authorization for sample retention for up to ten years if no genetic testing
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is performed; however, informed consent must be obtained prior to the conduct of genetic
tests.160
On the other hand, for research (rather than for clinical purposes), New York law provides
that samples may be used without individual informed consent when IRB approval of the
research protocol is given, as long as the identity of the individual has been removed, the results
are not linked to the person, and no information relating to the identity of the individual is
disclosed.161 Therefore, for the purposes of compliance with the New York law, the samples and
data may be used as proposed, as long as IRB approval is obtained, and the information
regarding individual identities is protected.162
Moreover, individual ownership of “genetic information” has been declared by four states:
Colorado, Florida, Georgia, and Louisiana.163 However, of the four states that declare that
genetic information is “owned” by the individual, three of them (Colorado, Georgia, and
Louisiana) permit the use of “genetic information” for research purposes when the identity of the
individual is not disclosed.164 Thus, while these provisions appear restrictive, they permit the use
and retention of genetic information for research purposes when the data are anonymous.165
Finally, Michigan and Nebraska also have identical statutes for the conduct of “genetic
tests,” which impose a strict requirement to obtain informed consent from individuals that
incorporates a statement of future uses of the sample and who will have access to the sample.166
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Both states permit research without informed consent when research is conducted pursuant to
federal regulations.167 Similarly, South Carolina imposes strict limits on the conduct of genetic
tests for clinical purposes, but permits the use of samples and information for research purposes
when patient identities are not disclosed.168
C. Synthesis
A noteworthy addition to the federal legislation has been the states’ broad definition of
“genetic information” or “genetic test” in conjunction with a comprehensive informed consent
procedure prior to any genetic testing/research. A broad definition of “genetic information” or
“genetic test” places most research within the scope of the statute.
Furthermore, a comprehensive informed consent procedure restricts the use and disclosure of
an individual’s identifiable genetic information. Generally, the informed consent form requests
information from the research participant regarding future use of the genetic sample, such as
permissible disclosures to third parties. Specifically, New York mandates that informed consent
must be obtained prior to any “genetic test.” Similarly, in New Jersey, all “genetic information”
must be destroyed after genetics research and/or genetic testing, unless the individual participant
provides otherwise. This ensures that an individual’s identifiable genetic information is not
being released to an unauthorized third party after the research and/or testing has been
completed.
Therefore, when the data of a genetic sample is not anonymous, certain states have
adequately protected the unauthorized disclosure of an individual’s “genetic information”
through an informed consent procedure prior to genetics research and/or testing.
167
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comprehensive informed consent procedure ensures that an individual’s identifiable genetic
information is not released to an unauthorized third party, thus preserving that individual’s
genetic privacy.
IV. Proposed

Recommendations

to

Preclude

Unauthorized

Disclosure

of

an

Individual’s Identifiable Genetic Information
Although genetics research provides invaluable information in the study and treatment of
diseases, there is a substantial privacy concern with respect to an individual’s identifiable genetic
information following the completion of genetics research and/or testing. There are certain
research entities that are not regulated by federal or state law and pose a threat to an individual’s
genetic privacy by freely disseminating an individual’s identifiable “genetic information”
without authorization.
Specifically, in order to address the ongoing privacy concerns of genetics research, the
following recommendations are proposed: (1) HIPAA should be amended to mandate that any
person or entity with access to an individual’s PHI must comply with HIPAA’s privacy
regulations; (2) a majority of states should adopt a statutory framework similar to New Jersey
and New York law, which include informed consent provisions, in order to preclude the
unauthorized disclosure of an individual’s identifiable genetic information; or (3) Congress
should preempt the entire field on this matter in order to establish more uniformity. These
changes will reach a balance that protects an individual’s genetic privacy while still allowing for
the scientific advancement of genetics research to progress for the benefit of humanity.
First, HIPAA could be amended to mandate that any person or entity with access to an
individual’s PHI must comply with the HIPAA privacy regulations. Most research laboratories
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or tissue banks do not fall within the definition of a “covered entity.” This amendment would
regulate those certain research laboratories or tissue banks that do genetics research/testing or
any other person that has access to an individual’s identifying “genetic information.” Thus, if a
research laboratory has done genetics research or testing, that research laboratory can only
disclose that individual’s identifying “genetic information” to the individual research participant,
or those necessary disclosures for the purpose of “treatment, payment, or health care operations.”
This amendment to HIPAA would ensure that confidentiality of an individual’s identifying
genetic information is preserved and only used or disclosed as needed.
Next, the states could adopt a statutory framework similar to New Jersey and New York in
order to preclude the unauthorized disclosure of an individual’s identifiable genetic information.
New Jersey mandates that unless the research participant authorizes otherwise, an individual’s
genetic information must be destroyed after the completion of genetic research or testing. Also,
New York mandates that informed consent must be obtained prior to any “genetic test.” The
informed consent requests information with regard to future use of the genetic sample, such as
authorized disclosures.

Furthermore, New York suggests a longer retention of genetic

information if anonymity is preserved along with IRB approval. Therefore, so long as there is no
identifying link between the sample and the research participant, then a longer retention of the
sample could be permissible.

Adopting a similar statutory framework will ensure that an

individual’s identifiable genetic information is not freely disseminated to unauthorized third
parties, such as employers and/or health care providers.
Finally, another option to precluding the unauthorized disclosure of an individual’s
identifiable genetic information could be for Congress to preempt the entire area of law on this
particular matter. HIPAA could be amended as the first proposal suggests to mandate that any
24

person or entity with access to an individual’s PHI must comply with the HIPAA privacy
regulations. Moreover, HIPAA could also be amended to incorporate similar informed consent
provisions as noted in the second proposal. As a result, there would be more uniformity on the
type of conduct that is regulated. This would establish a more “national and uniform basic
standard,” as originally intended by Congress, and ensure the confidentiality of an individual’s
identifiable genetic information is preserved. More uniformity is necessary in order to create
less confusion on the type of conduct that is regulated.
Although the proposed amendments to HIPAA may establish more uniformity it is likely not
a practicable recommendation. It would probably take Congress many years to amend a federal
statute, such as HIPAA. In order to effectively regulate research laboratories and tissue banks,
the states will probably have to continue to take the initiative by establishing comprehensive
informed consent procedures prior to any “genetic test.” A comprehensive informed consent
procedure will ensure that an individual’s identifiable genetic information is not disclosed to an
unauthorized third party, such as employers and/or health insurance providers. Also, expanding
the definition of what constitutes a “genetic test” will ensure that certain research laboratories
and tissue banks are properly regulated.
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V. Conclusion
Genetics research is critical to the study and treatment of diseases; however, there is a
substantial privacy concern with respect to an individual’s identifiable genetic information after
the research and/or testing has been completed. Certain research laboratories or other entities not
covered under federal or state legislation may freely disseminate an individual’s identifiable
genetic information to third parties, which could result in various types of discrimination by
employers and/or health insurance providers. The aforementioned proposals would preserve the
confidentiality of an individual’s identifiable genetic information while still allowing for the
scientific advancement of genetics research in order to benefit humanity.
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